Cancer Treatment through Plant-Based Vaccines: A Promising Approach

Hina Ghafar[1], Laiba Saher[2], Hifsa Mobeen[3], Muhammad Adnan[4], Ihsan Ullah[5], Saeeda Naz[6], Mohsin Rasool[7]

[1]Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad (UAF), Pakistan

[2]Agriculture Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan

[3]Ph.D. Scholar (Microbiology), Institute of Molecular Biology and Biotechnology, The University of Lahore & Department of Medical Lab Technology - AHS, Superior University Lahore, Pakistan

[4]Department of Plant Pathology and University of Agriculture Faisalabad

[5]Department of Biosciences, COMSATS University Islamabad, Pakistan

Email: ihsan.biotech@gmail.com

[6]National Medicinal Aromatic Plants And Herbs Programme (NMAPAHP), PGRI, NARC, ISLAMABAD

[7]Department of Entomology, University of Agriculture Faisalabad

Corresponding Author: Ihsan Ullah, Department of Biosciences, COMSATS University Islamabad, Pakistan, Email: ihsan.biotech@gmail.com

ABSTRACT

Cancer remains one of the most significant global health challenges, necessitating the development of innovative therapeutic approaches. Traditional treatments, such as chemotherapy and radiation therapy, often have severe side effects and limited specificity. In recent years, plant-based vaccines have emerged as a promising alternative for cancer immunotherapy, leveraging the ability of plant-derived compounds to stimulate immune responses and target tumor cells effectively. These vaccines are engineered to express tumor-associated antigens (TAAs), which activate the immune system to recognize and eliminate cancerous cells. Advancements in biotechnology have facilitated the cost-effective production of plant-based vaccines, utilizing genetically modified plants to express recombinant proteins. Their potential for oral administration enhances patient compliance and eliminates the need for complex storage and transportation logistics. Additionally, the incorporation of plant-derived adjuvants can significantly improve the immunogenicity of these vaccines, making them more effective in cancer treatment. Recent research highlights the role of plant viral nanoparticles in activating immune responses and generating long-lasting protection against tumor recurrence. Moreover, the integration of nanotechnology further enhances vaccine delivery and stability, ensuring targeted immune activation. Despite their advantages, plant-based vaccines face challenges such as low protein yield, stability issues, regulatory hurdles, and concerns about allergenicity. Addressing these limitations through advances in genetic engineering, formulation techniques, and regulatory frameworks will be critical for their successful clinical translation. As research progresses, plant-based vaccines have the potential to revolutionize cancer immunotherapy by providing safer, cost-effective, and widely accessible treatment options. Their ability to stimulate immune responses while also exhibiting intrinsic anticancer properties underscores their potential as a transformative strategy in cancer treatment.

Keywords: cancer, immunotherapy, vaccines, biotechnology, nanotechnology

1. Introduction

Recently, plant-derived vaccines potential as a cancer treatment has created immense interest. This approach takes advantage of the plant's unique compounds to improve the effectiveness of

cancer immunotherapy. Vaccines of this nature can be made to produce associated antigens of tumors that trigger a strong immune response and are proficient in combating cancer. This method provides a new treatment option and overcomes the challenges posed by other cancer treatment methods like chemotherapy and radiation which are usually very non-specific, very general, and damaging (Fiore et al., 2015; Karachi, 2019).

Developments in biotechnology hav made it possible to create vaccines with the help of plants in a much cheaper way than before. An example would be utilizing modified plants to emit proteins that can be used in cancer vaccines. The best part about these vaccines is that they can be taken in orally unlike the normal injectable vaccines – thus increasing adherence to vaccination and eliminating the need for cold storage (Meriç et al., 2021; Salim, 2024). Also, using plant materials as adjuvants can make these vaccines more efficacious (Kazi et al., 2024).

Research focuses on how cancer gets treated differently, such as utilizing plant based vaccines. The studies show that these vaccines trigger certain immune responses that are specific towards tumor interacting antigens. An example can be seen with the plant viral nanoparticles, which can enhance the immune system as well achieve a systemic integration of antitumor response within primary tumor models of melanoma and breast cancer (Murray et al. 2019). These vaccines can further promote the recall response for the immune system, achieving long-term defense against cancer reemergence (Murray et al., 2019). This phenomenon is crucial for aiding in cases of cancer as there are larger chances of metastasis and reoccurrence of cancer.

Furthermore, the combination of nanotechnology with plant-based vaccines is a new frontier when it comes to improving vaccine delivery and efficacy. Vaccine antigens can be loaded into nanoparticles for improved stability and targeting to antigen presenting cells (Kızılbey et al. 2021; Wang & Lu, 2018). This allows for enhancing the immune response to cancer due to more active T cells and a better overall reaction to the cancer cells (Kızılbey et al., 2021). Moreover, plant extract as natural adjuvants can increase the immune response to plant made vaccines in cancer immunotherapy (Kazi et al., 2024).

The advantages of plant vaccines extend beyond generating immune responses. Some compounds derived from plants already have certain intrinsic anticancer activities that complement vaccine efficacy. For example, several medicinal plants have been reported to contain phytochemicals with significant anticancer cytotoxic activity, which can improve the quality of therapy (Yadav & Koshi, 2022; Hassan, 2020). Such action of vaccines from plants is

presented as a progression in medical technology because these vaccines not only boost immunity but also have direct anticancer activity, which makes these vaccines a suitable choice for a cancer preventive strategy.

The other positive side of plant vaccines is their eco-friendliness, especially in comparison with conventional vaccine manufacturing processes. Vaccine-producing plants are more sustainable than animal cell culture systems that are costly and ethically troubling (Meriç et al., 2021; Salim, 2024). Moreover, expansion of plant vaccine production can lower cost, improving affordability and accessibility to many people (Meriç et al., 2021; Salim, 2024).

Research into plant-based vaccines to cure cancer is backed by increasing literature which describes their usefulness as an alternative to conventional therapies. There is evidence noting the successful use of plant-based vaccines for a variety of cancers, including melanoma, colorectal cancer, and breast cancer (Murray et al., 2019; Mak et al., 2016). These encouraging preclinical and early clinical trial results demand further investigation and refinement of these novel therapeutical approaches.

In conclusion, plant-based vaccines offer a new and innovative automotive treatment for cancer as they are capable of utilizing the benefits modern immunotherapy offers as well as the unique features of other stratified plant-based substances. These features might aid the body in combating cancer and thus might serve as a great new addition to the arsenal of cancer therapies. With extensive research in this area, plant-based vaccines can prove to be the next big thing when it comes to efficient, sustainable, and easy to avail cancer treatment solutions.

2. The Mechanism of Plant-based Cancer Vaccines

Vaccines that are made from the extract of tumor plants within them involve a definite sequence of events that utilize the distinctive features of plants to produce and elicit an immune response towards tumor cells. This process starts with gene cloning and transformation, which involves putting TAAs or immune stimulating molecule encoding genes into plant expression vectors. The plant cells are then controlled transformed using Agrobacterium or biolistic methods known as gene gun methods (Lü et al., 2012). This step is very important because it impacts the success and effectiveness of the following steps of protein expression in the system.

After a successful transformation has been done, the next phase is the growing of the transformed plants. This step is crucial for the large scale production of target antigen proteins. For optimal growth and protein expression, the plants are grown in specific conditions that allow

for the total accumulation of recombinant proteins (Lee et al., 2011). Among the various benefits of producing proteins using plants is the high biomass yield and the absence of endotoxins that are common in bacterial cultures used in protein synthesis (Lee et al., 2011).sThis feature enhances vaccine safety and makes the production of the vaccine cheaper.

After the growth period is achieved, and the expression of the targeted proteins has been performed, the subsequent stage is purification and formulation. The plant tissues are harvested, and the antigenic proteins are separated from the tissues, purified, and formulated into the appropriate vaccine dosage forms ready for administration (Lee & Ko, 2017). The purification step is very important to guarantee that the vaccine has been processed to be safe and effective on human patients. Some formulations might also serve as adjuvants to boost the immune response, which makes the vaccine more effective (Hager et al., 2022).

Vaccines made from plants can be administered through multiple ways, including, orally, intranasally, and injections. Oral delivery is advantageous as it simplifies administration and eliminates the need for sterile needles as well as refrigeration that comes with normal injections. (Shin et al., 2023). This method increases patient compliance and the use of edible plants as vaccine carriers, especially in low resource areas. (Saba et al., 2020). After administration, the vaccine stimulates an immune response that produces antibodies and activates T cells that target cancer cells with specific TAAs and destroy them. (Lü et al., 2012).

Studies have shown the effectiveness of plant-based vaccines and its ability to generate an immune response. For example, the use of vaccines made from plants has shown to produce single-chain variable fragments (scFv) proteins that have both humoral and cytotoxic T cell immunity against cancer cells. (Lee & Ko, 2017). This dual action is particularly crucial in cancer immunotherapy as it makes the treatment more holistic and effective by bringing the full capability of the immune system into play.

In addition, the utilization of plants as bioreactors for a vaccine production system has numerous notable additional advantages. The flexibility of plant based systems permits prompt response to public health challenges like pandemics or novel cancer types as vaccines can be quickly produced (Hager et al., 2022). The global cultivation of these plants in different regions further adds to the possibility of this approach, as it serves as an intriguing substitute to the conventional and vaccine production processes, which are almost always expensive and complicated fermentation based methods, (Park et al., 2022).

To sum up, the process by which plants are engineered to produce cancer vaccines involves several seamless processes like gene cloning and transformation, protein expression, purification, and delivery. These innovative approaches not only take advantage of the need to produce TAAs within elevated plant systems, but they also have the potential to transform the entire field of cancer immunotherapy by presenting safe and effective vaccines that are easy to administer. As researches in this domain continue to grow, the hope for plant based vaccines as a prominent constituent in cancer treatment becomes more attainable.

3. Benefits of Using Plants for Vaccines for Cancer Treatment

Other pros that stem from the use of plants for cancer treatment vaccines include low costs, high safety, easy production, and strong immune response stimulation. Each of these factors adds a unique dimension to the potential of using systems derived from plants, especially considering its relevance in cancer immunotherapy.

3.1 Cost-Effectiveness

Cost challenge is addressed by plant vaccines as they seem to outperform traditional vaccine production approaches which utilize bacterial or mammalian methods. As discussed Shi et al. (2022), plant based systems have basically no infrastructural requirements because they can be grown in open fields or greenhouses which do not require the construction of expensive bioreactors and elaborate laboratory setups. Such simplicity does not just decrease initial investment cost, but also cuts down costs incurred while handling sterile environments and specialized equipment. Additionally, plants cultivated for vaccine production can be easily cultivated on a larger scale for mass production, especially in response to public health challenges like during cancer treatment campaigns in poorer parts of the world. Moreover, the incorporation of plants as bioreactors allows for enormous savings on downstream processing cost, as the extensive purification and sterilization procedures that are the norm for other methods are at times completely unnecessary (Demone et al., 2022).

3.2 Risks Associated with Safety and Contamination

Plant based vaccines do provide a benefit with regards to safety. Unlike Traditional animal cell culture vaccines, plant-based vaccines do not run the risk of contamination with animal cells. The presence of animal and its diseases, including viral and prion, tell us that such vaccines are dangerous. This is quite critical around cancer treatment where patient’s immunity may already be in danger. Unsurprisingly, the absence of animal components improves the safety profile of

the vaccine even further. Furthermore, removing animal proteins eliminates the risk of adverse reactions. In the same line of thought, using plants as vaccines does allow post-translational treatment and glycosylation of the proteins, making sure the vaccine is stable and has immune response potential without the contamination risks (Sohn et al, 2023).

3.3 Scalability and Rapid Production

One of the key strengths is the expansion of the production of plant molecular agriculture vaccines in response to global health problems. For example, plants can be grown in large areas, which guarantees high vaccine output within a short time period (Park et al., 2021). This feature is mostly crucial in addressing matters of great health importance such as disease outbreaks and providing cancer therapy in vulnerable regions. The rapid response to health dangers made possible by the quick production of plant-derived vaccines makes the idea of using this approach very efficient. In addition, the cultivation of plants in many ecological zones increases the chances of achieving vaccine production in different parts of the world, thereby enhancing the availability of life saving therapies (Wang et al., 2020).

3.4 Induction of Strong Immune Response

A vaccine sourced from plant cells could be useful for a person suffering from cancer tumor. This is because these cells are capable of triggering vigorous immune actions and responses. Such vaccines could be designed to contain immune-stimulatory adjuvant which will help in targeting and defeating cancer cells. With the addition of these adjuvants, specific “helping” immune responses cans be achieved which facilitates both humoral and cellular elements of immunity, which are vital for combating cases of tumors. Research indicates that vaccine made from plants can induce potent antibodies and active T cells which are vital for capturing and extermination of cancer cells (Song et al., 2021). These features make plant-based vaccines highly applicable to immunotherapy and possibly boost the health status of a cancer patient.

In conclusion, these features make plant-based vaccines highly applicable to immunotherapy and possibly improve the health status of patients with cancer. Regardless of the alarming statistics, the benefits brought about through plant-based vaccine methods for cancer patients are undeniable. The fact that these vaccines are inexpensive, safe as well as easy to manufacture while at the same time having the capacity to provoke heightened immune responses puts them in a class of their own when compared to standard vaccines. But as more works are done in this

area, plant-based vaccines are bound to have a major impact in treating cancer and provide a ray of hope for patients around the globe.

4. Problems and Restrains

When creating and using plant-derived cancer vaccines, a number of problems and obstacles come up that need to be solved if these vaccines are to be effective. These worries include yield and stability issues, regulatory problems, and allergenicity and immune tolerance concerns, among others. Each of these conditions affect plant-derived vaccines' feasibility and effectiveness for use in clinical settings.

4.1 Low Yield And Its Stabity Problems

A significant drawback of vaccines produced from plants is their low yield of recombinant proteins as compared to traditional host expression systems, such as bacteria or mammalian cell cultures. The efficiency of protein expression in plants can be influenced by different factors like the type of a plant tissue used, species of the plant, and method of transformation like Agrobacterium infection or bombardment of microprojectiles (Campero, 2024). Thus, obtaining commercially feasible therapeutic proteins becomes problematic. Furthermore, the stability of these proteins is equally important and poses a challenge especially with regards to storage and transport. A number of recombinant proteins synthesized in plants are susceptible to degradation and denaturation which renders them useless as vaccines (Eerde et al., 2019). Hence, proteins have to be modified in a way which would enhance their stability and make them useful for clinical applications (Park, 2023).

4.2 Existing Legal Framework and Approvals

Plants, like many other forms of medicines and treatments offer strong prospects for curing human ailments, and while that is certainly the case, entrepreneurs are bound by many local legal regulations that may drastically limit their ability to obtain any form of regulatory approval. Like any other vaccine, plant-based vaccines pass through a set of clinical trials, and go through proper checks to make sure the end product is neither harmful nor ineffective (Uversky et al, 2023). Due to the innovation's method of production and the usage of genetically modified organisms, plant based vaccines capture a lot of attention which make it even more difficult to go through the intricate process. Authorities and regulators seek thorough information regarding the allergenicity, safety and immunogenicity of the plant based vaccines (Mbongue et al., 2019). Due to the highly sensitive nature of the governance set in place, there is a strong limitation on

the effective and timely utilization of plant based vaccines within the public eye, leading to more dire issues within public health

4.3 Allergenic Potential and Immune Tolerance

The allergenicity of the vaccine is another important issue of plant-based vaccines. Some people may have an allergic response due to the incorporation of plant proteins in the vaccine (Smith et al., 2019). This problem is especially relevant for oral vaccines, as the sensitivity of the gastrointestinal tract to certain proteins may provoke a negative immune response. Furthermore, the oral route of administration may have the unwanted consequence of immune tolerance instead of immune sensitization. Immune tolerance occurs when the body's immune system ceases to react to a particular antigen leading to reduced effectiveness of the vaccine (Chung et al., 2021). In order to solve these problems, it is necessary to increase the immunogenicity of the vaccine while reducing the chances of allergenic and immune tolerant responses. This includes but is not limited to adding adjuvants or using certain types of plants that are known to have low allergenic activity (Cobb et al., 2023).

To sum up, the advancement of plant biotechnology for the development of novel vaccines that are aimed at treating cancer and cancerous cells has its pros and cons. The innovation presents difficulties such as yield and stability, regulations, immune system tolerance, and allergic reactions. The development of these modern therapeutic frameworks needs to be focused on these issues as a priority. These barriers have to be overcome during the ongoing advancement of this area to achieve effective plant-derived vaccines for practical use. That is a goal that needs to be achieved. To do that, provided barriers need to be addressed, and only then will it be easy to achieve real-life applications of these plant-derived vaccines.

5. Conclusion

Advancements in biotechnology as well as a continually increasing understanding of the immune systems intricacies paints a positive future picture of plant based vaccines in cancer treatments. While research developments are constantly being made, some areas will greatly influence the use and development of these vaccines.

The use of plant-based vaccines with other treatment approaches, in particular, traditional methods and new immunotherapy, is the most important future direction for these vaccines. Plant-based vaccines could be used with checkpoint inhibitors or monoclonal antibodies to

strengthen the treatment efficacy of cancer vaccines Lin et al. (2020). By using the different therapeutic approaches, we may improve patient outcomes. Besides, the immune response can be strengthened by the use of plant-derived adjuvants in conjunction with other cancer treatments (Chen, 2015).

The new techniques in genetic engineering, such as CRISPR/Cas9 and synthetic biology, are expected to be very helpful in the future of plant-based vaccines. These modern technologies facilitate the modification of plant genomes at the molecular level with the aim of increasing the expression of tumor angiogenic factors (TAAs) proteins while enhancing the stability and immunogenicity of the produced proteins (Waheed et al., 2010). Researchers are able to design more effective vaccines that stimulate sustained immune reactions toward cancer cells by constructing optimal genetic sequences for use in plant expression systems. In addition, the ability to genetically engineer plants to express the coat proteins of plant viruses for the production of virus-like particles (VLPs) can lead to vaccines with highly immunogenic properties that are more effective in stimulating the immune response (Landry et al., 2010).

Regulatory issues are barriers that, if solved, would allow plant-based vaccines to be used within clinical practice. There needs to be a joint effort among image scientists, regulating bodies, and policy makers to develop criteria for issuing licenses and marketing plant vaccines (Delany et al., 2014). This involves completing well-structured clinical trials to prove safety and efficacy, as well as tackling negative perceptions concerning the use of GMOs for vaccine production. Plant-based vaccines would be easier to accept with more openness and public involvement, especially for use in the treatment of cancer.

As with any new technology, plant-based vaccines present a powerful opportunity to increase global health equity. Their affordability and ease of production would certainly help with cancer treatment inequities in low-middle income countries (Lee & Ko, 2017). Through these regions where traditional therapies are absent, plant-based vaccines would be one more approach in the effort against cancer. The endeavor to establish local production plants for plant-based vaccines would increase vaccine supply, reduce dependency on imported vaccines, and enhance the health status of the underprivileged (Zhao et al., 2018).

In the not-so-distant future, treating cancer is likely to move towards the use of personalized medicine. With their extensive potential, plant-based vaccines stand poised and ready to aid along this shift. Innovative approaches to tumor heterogeneity and the immune

microenvironment of the patients enables the design of personalized vaccines aimed at specific tumor antigens for each patient (Li et al., 2022). Through the application of plant expression systems for modular vaccine design, clinicians may be able to augment the effectiveness of immunotherapy and enhance patient responses. This method of personalization can also be applied to create multi-targeted therapies that involve plant-based vaccines and other strategies to further improve efficiency of treatment (Cosma & Eisenlohr, 2018).

To conclude, plant-based vaccines are a hopeful innovation in cancer treatment because they can be cost-effective, safe, and potent in eliciting immune responses. Even though there are still some unresolved issues with yield and stability, regulative approval, and allergenicity, ongoing research and technological improvements hope to solve these problems. The future of global health equity as well as the combination of plant-based vaccines with other therapies, improvements in genetic engineering, and focus on holistic health will change the prognosis of cancer immunotherapy. With further developments in this field, plant-based vaccines may fundamentally change how cancer is treated and bring a new sense of hope to patients around the world.

6. References

1. Michele Fiore, Baptiste Thomas, Gour Chand Daskhan & Olivier Renaudet (2015). Synthetic Vaccines against Cancers. *nan*, nan(nan), 357-378. https://doi.org/10.1142/9781783267200_0014
2. Aida Karachi (2019). Immunotherapy for Treatment of Cancer. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.81150
3. Sinan Meriç, Tamer Gümüş & Alp Ayan (2021). Plant-based Vaccines: The Future of Preventive Healthcare?. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.97861
4. Siham A. Salim (2024). Medicinal Plants as Sources for Drugs and Vaccines. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.113766
5. Nazmul Kazi, John Warren Kindt, Indika Kahanda, Christopher da Costa, Robert H. Carnahan, Hugh S. Mason, Brenda A. Wilson & S. Indu Rupassara (2024). Perspective Chapter: Natural Adjuvants for Mucosal Vaccines – The Promise of Tomatine as an Inherent Adjuvant in Tomatoes. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.112932
6. Abner A. Murray, Mee Rie Sheen, Frank A. Veliz, Steven Fiering & Nicole F. Steinmetz (2019). In Situ Vaccination of Tumors Using Plant Viral Nanoparticles. *nan*, nan(nan), 111-124. https://doi.org/10.1007/978-1-4939-9516-5_10
7. Kadriye Kızılbey, Nelisa Türkoğlu & Fatma Ceren Kırmızıtaş (2021). Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.94560
8. Shouju Wang & Guangming Lu (2018). Applications of Gold Nanoparticles in Cancer Imaging and Treatment. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.70901
9. Sangilimuthu Alagar Yadav & Feba Sara Koshi (2022). Phytochemicals from Solanaceae Family and Their Anticancer Properties. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.104462
10. Bassam Abdul Rasool Hassan (2020). Plants and Cancer Treatment. *nan*, nan(nan), nan. https://doi.org/10.5772/intechopen.90568
11. Gabriel Mak, Michele Moschetta & Hendrik-Tobias Arkenau (2016). Immunotherapy in Colorectal Cancer. *nan*, nan(nan), nan. https://doi.org/10.5772/63136
12. Zhe Lü, Kyung Jin Lee, Yingxue Shao, Jeong Hwan Lee, Yangkang So, Young-Kug Choo, Doo-Byoung Oh, Kyung-A Hwang, Seung Han Oh, Yeon Soo Han & Kisung Ko (2012). Expression of GA733-Fc Fusion Protein as a Vaccine Candidate for Colorectal Cancer in Transgenic Plants.

Journal of Biomedicine and Biotechnology, 2012.0(nan), 1-11. https://doi.org/10.1155/2012/364240

13. Choonghee Lee, Hyung-Hwan Kim, Kyung K. Choi, Kyu-Rhim Chung, Yien Kyoung Choi, Mi Jung Jang, Tong-Soo Kim, Nam-Jun Chung, Ho-Gun Rhie, Ho-Sa Lee, Youngjoo Sohn, Hyuck Kim, Sung-Jae Lee & Hyeong-Woo Lee (2011). Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. *Malaria Journal*, 10.0(1.0), nan. https://doi.org/10.1186/1475-2875-10-106
14. Jeong-Hwan Lee & Kisung Ko (2017). Production of Recombinant Anti-Cancer Vaccines in Plants. *Biomolecules & Therapeutics*, 25.0(4.0), 345-353. https://doi.org/10.4062/biomolther.2016.126
15. Karen Hager, Gonzalo Pérez Marc, Philipe Gobeil, Ricardo Sobhie Diaz, Gretchen Heizer, Conrado J. Llapur, A. И. Макарков, Eduardo Vasconcellos, Stéphane Pillet, Fernando Riera, Pooja Saxena, Priscila Geller Wolff, Kapil Bhutada, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Luciana Ferrara, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurélien Lorin, Asif Mahmood, Lawrence H. Moulton, Emmy Pahmer, Julie Parent, Annie Séguin, Luan T. Tran, Thomas Breuer, Maria-Angeles Ceregido, Marguerite Koutsoukos, François Roman, Junya Namba, Marc-André D'Aoust, Sonia Trépanier, Yosuke Kimura & Brian J. Ward (2022). Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. *New England Journal of Medicine*, 386.0(22.0), 2084-2096. https://doi.org/10.1056/nejmoa2201300
16. Minna Shin, Hyangju Kang, Kyeong ryeol Shin, Rangyeon Lee, Kiju Kim, Kyungmin Min, Kyou-Nam Cho, Eun-Ju Sohn, Kwang Sung Kim, Seok-Hyun Kim, Yang Je Cho, Jeongho Park & Tae-Wook Hahn (2023). Plant-expressed Zika virus envelope protein elicited protective immunity against the Zika virus in immunocompetent mice. *Scientific Reports*, 13.0(1.0), nan. https://doi.org/10.1038/s41598-023-47428-7
17. Kiran Saba, Muhammad Sameeullah, Asba Asghar, Johanna Gottschamel, Sara Latif, Andreas Günter Lössl, Bushra Mirza, Osman Mirza & Mohammad Tahir Waheed (2020). Expression of ESAT-6 antigen from Mycobacterium tuberculosis in broccoli: An edible plant. *Biotechnology and Applied Biochemistry*, 67.0(1.0), 148-157. https://doi.org/10.1002/bab.1867

18. Se Hee Park, Kon-Young Ji, Seo Young Park, Hyun Min Kim, Sang Hoon, Ju Hui, Hyeonggon Kang, Hyung Sik Kang, Doo-Byoung Oh, Jae Sung Shim & Young Hee Joung (2022). Immunotherapeutic effects of recombinant colorectal cancer antigen produced in tomato fruits. *Scientific Reports*, 12.0(1.0), nan. https://doi.org/10.1038/s41598-022-13839-1
19. Yao Shi, Peyman Habibi, Ayesha Naveed Ul Haq, Madiha Saeed, Namra Gulghutay Amjad & Imran Khan (2022). Seed-Based System for Cost-Effective Production of Vaccine Against Chronic Respiratory Disease in Chickens. *Molecular Biotechnology*, nan(nan), nan. https://doi.org/10.1007/s12033-022-00554-5
20. Jordan Demone, Mariam Maltseva, Maryam Nourimand, Mina Nasr-Sharif, Yannick Galipeau, Emilio I. Alarcon, Marc-André Langlois & Allyson M. MacLean (2022). Scalable agroinfiltration-based production of SARS-CoV-2 antigens for use in diagnostic assays and subunit vaccines. *Plos One*, 17.0(12.0), e0277668. https://doi.org/10.1371/journal.pone.0277668
21. Kee Hwan Park (2023). Field evaluation of novel plant-derived porcine circovirus type 2 vaccine related to subclinical infection. *Veterinary Medicine and Science*, 9.0(6.0), 2703-2710. https://doi.org/10.1002/vms3.1256
22. Eun-Ju Sohn, Hyangju Kang, Kyungmin Min, Min Hee Park, Ju-Hun Kim, Hwa-Jung Seo, Sang-Joon Lee, Heeyeon Kim, Dongseob Tark, Ho-Seong Cho, Bo-Hwa Choi & Yeonsu Oh (2023). A Plant-Derived Maternal Vaccine against Porcine Epidemic Diarrhea Protects Piglets through Maternally Derived Immunity. *Vaccines*, 11.0(5.0), 965. https://doi.org/10.3390/vaccines11050965
23. Young-Min Park, Hyangju Kang, Kyungmin Min, Nam Hyung Kim, Min Hee Park, In-Ohk Ouh, Ha-Hyun Kim, Jae-Young Song, Dong-Kun Yang, Eun-Ju Sohn & Sang-Min Lee (2021). Rabies virus glycoprotein produced in Nicotiana benthamiana is an immunogenic antigen in mice. *Czech Journal of Genetics and Plant Breeding*, 57.0(1.0), 26-35. https://doi.org/10.17221/25/2020-cjgpb
24. Maopeng Wang, Tingting Fu, Jiayi Hao, Letian Li, Mingyao Tian, Ningyi Jin, Linzhu Ren & Chang Li (2020). A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2. *International Journal of Biological Macromolecules*, 160.0(nan), 736-740. https://doi.org/10.1016/j.ijbiomac.2020.05.239

25. Bassel Akache, Tyler M. Renner, Anh Tran, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Diana Duque, Julie Haukenfrers, Martín A. Rossotti, Francis Gaudreault, Usha D. Hemraz, Edmond Lam, Sophie Régnier, Wangxue Chen, Christian Gervais, Matthew Stuible, Lakshmi Krishnan, Yves Durocher & Michael J. McCluskie (2021). Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. *Scientific Reports*, 11.0(1.0), nan. https://doi.org/10.1038/s41598-021-01363-7
26. Shi-Jian Song, Gyeong-Im Shin, Jin-Yong Noh, Ji-Ho Lee, Deok-Hwan Kim, Gyeong Ryul Ryu, Gyeongik Ahn, Jeon Hm, Hai-Ping Diao, Youngmin Park, Min Gab Kim, Woe-Yeon Kim, Young-Jin Kim, Eun-Ju Sohn, Chang Seon Song & Inhwan Hwang (2021). Plant-based, adjuvant-free, potent multivalent vaccines for avian influenza virus via Lactococcus surface display. *Journal of Integrative Plant Biology*, 63.0(8.0), 1505-1520. https://doi.org/10.1111/jipb.13141
27. Lucía M. Campero (2024). Immunization with Plant-based Vaccine ExpressingToxoplasma gondiiSAG1 Fused to Plant HSP90 Elicits Protective Immune Response in Lambs. *nan*, nan(nan), nan. https://doi.org/10.1101/2024.11.15.623790
28. André van Eerde, Johanna Gottschamel, Ralph Bock, Kristine Eraker Aasland Hansen, Hetron Mweemba Munang'andu, Henry Daniell & Jihong Liu Clarke (2019). Production of tetravalent dengue virus envelope protein domain <scp>III</scp> based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development. *Plant Biotechnology Journal*, 17.0(7.0), 1408-1417. https://doi.org/10.1111/pbi.13065
29. Kee Hwan Park (2023). Field evaluation of novel plant-derived porcine circovirus type 2 vaccine related to subclinical infection. *Veterinary Medicine and Science*, 9.0(6.0), 2703-2710. https://doi.org/10.1002/vms3.1256
30. Vladimir N. Uversky, Elrashdy M. Redwan, William Makis & Alberto Rubio-Casillas (2023). IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2'spike Protein by Suppressing the Immune System. *nan*, nan(nan), nan. https://doi.org/10.20944/preprints202303.0441.v1
31. Jacques C. Mbongue, Jeffrey Rawson, Pablo Andrés García, Nelson Gonzalez, Jacob Cobb, Fouad Kandeel, Kevin Ferreri & Mohamed I. Husseiny (2019). Reversal of New Onset Type 1 Diabetes by Oral Salmonella-Based Combination Therapy and Mediated by Regulatory T-Cells

in NOD Mice. *Frontiers in Immunology*, 10.0(nan), nan. https://doi.org/10.3389/fimmu.2019.00320

32. Tanja Smith, Martha M. O'Kennedy, Daniel B.R. Wandrag, Modupeore Adeyemi & Célia Abolnik (2019). Efficacy of a plant-produced virus-like particle vaccine in chickens challenged with Influenza A H6N2 virus. *Plant Biotechnology Journal*, 18.0(2.0), 502-512. https://doi.org/10.1111/pbi.13219
33. Young Hun Chung, Derek C. Church, Edward C. Koellhoffer, Elizabeth O. Osota, Sourabh Shukla, Edward P. Rybicki, Jonathan K. Pokorski & Nicole F. Steinmetz (2021). Integrating plant molecular farming and materials research for next-generation vaccines. *Nature Reviews Materials*, 7.0(5.0), 372-388. https://doi.org/10.1038/s41578-021-00399-5
34. Jacob Cobb, Sameh S. M. Soliman, Mauricio Retuerto, Janine C. Quijano, Chris Orr, Mahmoud A. Ghannoum, Fouad Kandeel & Mohamed I. Husseiny (2023). Changes in the gut microbiota of NOD mice in response to an oral Salmonella-based vaccine against type 1 diabetes. *Plos One*, 18.0(5.0), e0285905. https://doi.org/10.1371/journal.pone.0285905
35. Kuan-Hung Lin, Shwu-fen Pan, Chiu-Chen Chen, Wen-Shian Li & Chih-Ming Chiang (2020). Expression of Human papillomavirus type 52 L1 capsid gene in Oryza sativa involved in cytoprotective activities. *Notulae Botanicae Horti Agrobotanici Cluj-Napoca*, 48.0(1.0), 40-52. https://doi.org/10.15835/nbha48111750
36. Qiang Chen (2015). Plant-made vaccines against West Nile virus are potent, safe, and economically feasible. *Biotechnology Journal*, 10.0(5.0), 671-680. https://doi.org/10.1002/biot.201400428
37. Mohammad Tahir Waheed, Nadja Thönes, Martin Müller, Syed Waqas Hassan, N. Mona Razavi, Elke Lössl, Hans-Peter Kaul & Andreas Günter Lössl (2010). Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines. *Transgenic Research*, 20.0(2.0), 271-282. https://doi.org/10.1007/s11248-010-9415-4
38. Nathalie Landry, Brian J. Ward, Sonia Trépanier, Emanuele Montomoli, Michèle Dargis, Giulia Lapini & Louis-P. Vézina (2010). Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. *Plos One*, 5.0(12.0), e15559. https://doi.org/10.1371/journal.pone.0015559

39. Isabel Delany, Rino Rappuoli & Ennio De Gregorio (2014). Vaccines for the 21st century. *Embo Molecular Medicine*, 6.0(6.0), 708-720. https://doi.org/10.1002/emmm.201403876
40. Jeong-Hwan Lee & Kisung Ko (2017). Production of Recombinant Anti-Cancer Vaccines in Plants. *Biomolecules & Therapeutics*, 25.0(4.0), 345-353. https://doi.org/10.4062/biomolther.2016.126
41. Yu Zhao, Yugang Guo & Li Tang (2018). Engineering cancer vaccines using stimuli-responsive biomaterials. *Nano Research*, 11.0(10.0), 5355-5371. https://doi.org/10.1007/s12274-018-2162-1
42. Hongjian Li, Kun Peng, Kai Yang, Wenbo Ma, Shaolong Qi, Yu Xia, Jiayi He, Xin Lin & Guocan Yu (2022). Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. *Theranostics*, 12.0(14.0), 6422-6436. https://doi.org/10.7150/thno.77350
43. Gabriela L. Cosma & Laurence C. Eisenlohr (2018). CD8+ T-cell responses in vaccination: reconsidering targets and function in the context of chronic antigen stimulation. *F1000research*, 7.0(nan), 508. https://doi.org/10.12688/f1000research.14115.1